Author： Nuti R. Martini G. Giovani S. Valenti R.
Publisher： Adis International
ISSN： 1173-2563
Source： Clinical Drug Investigation, Vol.19, Iss.1, 2000-01, pp. : 55-61
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis
Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. :
Access to resources
Recommend
By Frediani B. Allegri A. Bisogno S. Marcolongo R.
Clinical Drug Investigation, Vol. 15, Iss. 3, 1998-03 ,pp. :
Use of low-dosage tricyclic antidepressants justified
Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. :
Alendronate: An Update of its Use in Osteoporosis
By Sharpe M. Noble S. Spencer C.M.
Drugs, Vol. 61, Iss. 7, 2001-01 ,pp. :